Treating diabetic retinopathy by tackling growth factor pathways.
Diabetic retinopathy (DR) remains a major cause of new cases of blindness onset in adults. The prevalence of diabetic eye disease is strongly related to the duration of diabetes, blood pressure and glycemic control, although a multifactorial pathogenesis is likely to be probable. Despite the effectiveness of current prevention (by tight metabolic and blood pressure control) and treatment (with laser photocoagulation) methods, and with the help of screening programs, diabetic eye disease is still a problem. Recent advances in our understanding of the pathogenesis of microvascular complications and particularly of the role of growth factors (GFs) in retinal changes have allowed significant advances in the medical management of DR. Studies of the biochemical process underlying DR have clearly demonstrated an important role for a number of aberrantly expressed GFs or their second messengers (eg, vascular endothelial growth factor, growth hormone, insulin-like growth factor-1, protein kinase C and pigment epithelium derived factor) possibly acting together in the development of structural changes characterizing early stages of vascular DR. The critical role of GF expression has led to new experimental therapeutic intervention in DR. In fact, timely pharmacological intervention in GF synthesis and activities may arrest the development of early vascular changes. As the effects of GFs become better understood, pharmacological manipulation of GF synthesis and action will be useful in the early stages of vascular change with the potential to prevent diabetes-related visual loss.
Chiarelli
Francesco
F
Department of Pediatrics, University of Chieti, Ospedale Policlinico, Via dei Vestini 5, I-66100 Chieti, Italy. chiarelli@unich.it
Giannini
Cosimo
C
Di Marzio
Daniele
D
Mohn
Angelika
A
D000818:Animals; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D005260:Female; D006133:Growth Substances / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans
D006133:Growth Substances